Skip to main content
Have a personal or library account? Click to login
Isovitexin can Alleviate Fracture-Related Infection, Promote Osteogenesis, and Inhibit Activation of the NF-κB Signaling Pathway Cover

Isovitexin can Alleviate Fracture-Related Infection, Promote Osteogenesis, and Inhibit Activation of the NF-κB Signaling Pathway

By:  and    
Open Access
|Jul 2026

References

  1. Abdulai IL, Kwofie SK, Gbewonyo WS et al. (2021) Multitargeted effects of vitexin and isovitexin on diabetes mellitus and its complications. Sci World J 2021:6641128. https://doi.org/10.1155/2021/6641128
  2. Cheng H (2025) Isovitexin: A promising active compound found in nature's bounty. Plant Foods Hum Nutr 80:197. https://doi.org/10.1007/s11130-025-01440-6
  3. Dai Y, Yi X, Huang Y et al. (2024) miR-345-3p modulates M1/M2 macrophage polarization to inhibit inflammation in bone infection via targeting MAP3K1 and NF-κB pathway. J Immunol 212:844–854. https://doi.org/10.4049/jimmunol.2300561
  4. Depypere M, Sliepen J, Onsea J et al. (2022) The microbiological etiology of fracture-related infection. Front Cell Infect Microbiol 12:934485. https://doi.org/10.3389/fcimb.2022.934485
  5. Dvorak JE, Lasinski AM, Romeo NM et al. (2024) Fracture related infection and sepsis in orthopedic trauma: A review. Surgery 176:535–540. https://doi.org/10.1016/j.surg.2024.04.031
  6. Fan Y, Chen Z, Wang H et al. (2025) Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis. Bone Res 13:18. https://doi.org/10.1038/s41413-024-00390-0
  7. Ferdausi N, Islam S, Rimti FH et al. (2022) Point-specific interactions of isovitexin with the neighboring amino acid residues of the hACE2 receptor as a targeted therapeutic agent in suppressing the SARS-CoV-2 influx mechanism. J Adv Vet Anim Res 9:230–240. https://doi.org/10.5455/javar.2022.i588
  8. Graan D, Balogh ZJ (2022) Microbiology of fracture related infections. J Orthop Surg 30:10225536221118512. https://doi.org/10.1177/10225536221118512
  9. He SY, Yu B, Jiang N (2023) Current concepts of fracture-related infection. Int J Clin Pract 2023:4839701. https://doi.org/10.1155/2023/4839701
  10. Kulkarni C, Kumar S, Khatoon S et al. (2025) Isovitexin, a natural adiponectin agonist, prevents glucocorticoid-induced osteosarcopenia. Endocrine 89:565–577. https://doi.org/10.1007/s12020-025-04251-6
  11. Matsumoto Y, Rottapel R (2020) Bone dynamics and inflammation: Lessons from rare diseases. Immunol Med 43:61–64. https://doi.org/10.1080/25785826.2020.1720104
  12. Moriarty TF, Metsemakers WJ, Morgenstern M et al. (2022) Fracture-related infection. Nat Rev Dis Primers 8:67. https://doi.org/10.1038/s41572-022-00396-0
  13. Novack DV (2011) Role of NF-κB in the skeleton. Cell Res 21:169–182. https://doi.org/10.1038/cr.2010.159
  14. Rothe R, Schulze S, Neuber C et al. (2019) Adjuvant drug-assisted bone healing: Part I - modulation of inflammation. Clin Hemorheol Microcirc 73:381–408. https://doi.org/10.3233/CH-199102
  15. Rupp M, Walter N, Bärtl S et al. (2024) Fracture-related infection-epidemiology, etiology, diagnosis, prevention, and treatment. Dtsch Arztebl Int 121:17–24. https://doi.org/10.3238/arztebl.m2023.0233
  16. Sun S, Wang Q, Zhang B et al. (2024) Vancomycin-loaded in situ gelled hydrogel as an antibacterial system for enhancing repair of infected bone defects. Int J Nanomedicine 19:10227–10245. https://doi.org/10.2147/IJN.S448876
  17. Sun X, Li P, Qu X et al. (2021) Isovitexin alleviates acute gouty arthritis in rats by inhibiting inflammation via the TLR4/MyD88/NF-κB pathway. Pharm Biol 59:1326–1333. https://doi.org/10.1080/13880209.2021.1979595
  18. Tian L, Wu X, Yu H et al. (2022) Isovitexin protects mice from methicillin-resistant staphylococcus aureus-induced pneumonia by targeting sortase A. J Microbiol Biotechnol 32:1284–1291. https://doi.org/10.4014/jmb.2206.06007
Language: English
Submitted on: Feb 9, 2026
Accepted on: May 19, 2026
Published on: Jul 13, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2026 Yaping Gu, Ping Xu, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.